Access, Innovation and Incentives: power for civilization to tackle cancer - and for better healthcare for ALL

Thursday, 19 October 2023 – Friday, 20 October 2023
Spanish National Cancer Research Center - CNIO,
C. de Melchor Fernández Almagro, 3, 28029 Madrid, Spain
Objective: Innovation and Incentives are changing the world we live in, and it has transformed struggling healthcare systems with new efficiencies, new therapies, new diagnostics, and new economies. Innovation through incentives has had an impact on healthcare, and new prospects of far greater advances open up daily. These series of sessions during ESMO will set out what frameworks can bring new precision to care, with benefits for patients and for society as a whole. But it also sets out the conditions for realizing the potential: key issues are ensuring adequate access to data, an appropriate regulatory environment, action to sustain innovation in research institutes and industries big and small, promotion of take-up of innovation by the healthcare establishment, and resolution of a range of vital legal and ethical questions centred on safeguarding patients and their rights. For Europe to fulfil the conditions for success, it will have to find a new spirit of cooperation that can overcome the handicaps of the continent’s fragmented technical and legal landscape. The start the European Union has made shows some ambition, but a clearer strategic vision and firmer plans for implementation will be needed.
Day I: Oct 19th

DEBATE 1
Sustainable access to existing treatment and incentivising development of new treatment: Is the EU falling behind?

DEBATE 2
Early Diagnosis and MRDs: Role of Liquid Biopsy and Screening Programmes: Can the potential be realised for the EU?

DEBATE 3
Turning intentions into action for the uptake of Next Generation Sequencing & Liquid Biopsy: Which Member State has been more successful?

DEBATE 4
Ensuring Access: Can clinical guidelines be aligned with policy Guidelines: The Reality vs the Idea?

Day II: Oct 20th

DEBATE 5
Disease Focused Sessions: Panc, Haem, Early Breast Cancer, Lung Cancer

DEBATE 6
Discussion: CAN.HEAL - Putting Patients at the Center

Moderator: Denis Horgan, Executive Director, European Alliance for Personalised Medicine
### Day I: Oct 19th

#### 08:15-09:15

**Registration and Networking**

**09:15-09:30**

**WELCOME**

**Núria Malats**, head of the Genetic and Molecular Epidemiology Group at the Spanish National Cancer Research Centre (CNIO)

**Marc Van den Bulcke**, Project Coordinator, CanHeal

**DEBATE 1: Sustainable access to existing treatment and incentivising development of new treatment: Is the EU falling behind?**

**Lung Cancer:** Luis Paz-Ares, Chair of the Medical Oncology Department at the Hospital Doce de Octubre (University Hospital October 12), Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center)

**Human Genetics:** Evelin Schröck heads the Institute for Clinical Genetics at the Carl Gustav Carus University Hospital at the Technical University of Dresden, Germany

**Innovator:** Michael Zaiac, Head of Medical Affairs Oncology EUCAN, Daiichi-Sankyo

**ICT Perspective:** Francisco Lupiañez-Villanueva, Co-founder and director of PredictBy and Professor at Open University of Catalonia

**Breast Cancer:** Mafalda Oliveira, Medical oncologist at the Medical Department of the Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO); Head of the SOLTI Breast Cancer Research Group

**Zero Cancer:** Ebba Hallersjo Hult, Head of the innovation milieu, Vision Zero Cancer, Sweden

**Precision Oncology and Biomarker Testing:** Mélanie Yammine, Director EU Government Affairs, EMEA Astellas Pharma

**Q&A**

**Debate & Discussion**

#### 09:30-11:00

**COFFEE**

#### 11:00-11:30

**DEBATE 2: Early Diagnosis and MRDs: Role of Liquid Biopsy and Screening Programmes: Can the potential be realised for the EU?**

**GI malignancies:** Teresa Macarulla, Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona, Spain

**Setting the Scene:** Paul Hofman, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Cote d’Azur, Nice, France

**Innovator:** John Longshore, Head of Scientific Affairs, AstraZeneca

**Ovarian Cancer:** Ettore D. Capoluongo, Prof. of Clinical Biochemistry and Clinical Molecular Biology, Director of Clinical Pathology Department, Emergency Hospital “Cannizzaro” - Catania (Italy)

**Innovator:** Benjamin Gannon, Vice President, International Guardant Health

**Haematology:** Guillermo Sanz, Head of Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

**Q&A**

**Debate & Discussion**
### 13:00-14:00

**LUNCH**

### 14:00-15:30

**DEBATE 3: Turning intentions into action for the uptake of Next Generation Sequencing & Liquid Biopsy: Which Member State has been more successful?**

**Patient:** Alfonso Aguaron, Lung Cancer Europe, Madrid, Spain  
**CGI-Clinics:** Olivia Tort, Project manager, Institute for Research in Biomedicine (IRB Barcelona)  
**Innovator:** Gina De Bonis, Medical Affairs Manager EMEA, Oncology, Illumina  
**Economics:** Manuel Garcia Gofin, Associate Professor of Applied Economics at Complutense University of Madrid  
**Innovator:** Philip Jermann, Thermo Fisher Scientific  
**Sarcoma:** Iara Martiñan, President, Asociación de Sarcomas de Galicia, ASARGA  
**Leukemia:** Anna Bigas, Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research Institute

**Q&A**  
**Debate & Discussion**

### 15:30-16:00

**COFFEE**

### 16:00-17:45

**DEBATE 4: Ensuring Access: Can clinical guidelines be aligned with policy Guidelines: The Reality vs the Idea?**

**Setting the Scene:** Ruggero De Maria, Presidente, Alleanza Contro il Cancro UNCAN.eu, a European Initiative to UNderstand CANcer  
**Patients:** Bettina Ryll, Member of the first EU Cancer Mission board  
**Clinical/Research:** Vivek Subbiah, M.D., Chief, Early Phase Drug Development, Sarah Cannon Research Institute, Nashville, TN, USA  
**Regional:** David Vicente, Director of the Comprehensive Plan for Oncology, Andalusia, Spain  
**Innovator:** Klaus Schlueter, Vice President & Head Global Medical & Scientific Affairs Europe, Middle East, Africa and Canada, MSD  
**Innovation:** Rossana Alessandrello, Innovation Unit, Agency for Health Quality and Assessment  
**Naureen Starling,** Consultant Medical Oncologist at The Royal Marsden NHS

**Q&A**

### 20:00

**Speakers Dinner by invitation only**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15-09:15</td>
<td>Registration and Networking</td>
</tr>
<tr>
<td>09:00-11:30</td>
<td>DEBATE 5: Diseases focused Sessions: Role of Data, NGS and Diagnosis &amp; HTA</td>
</tr>
<tr>
<td>09:00-10:00</td>
<td><strong>GROUP 1:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Sarcoma:</strong> Iwona Lugowska, Early Phase Clinical Trials Unit and Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National, Research Institute and Oncology Centre (MSCI), Warsaw</td>
</tr>
<tr>
<td></td>
<td><strong>HTA:</strong> Iñaki Iñaki Iglesia. Scientific Researcher at AETS (Spanish Health Technology Assessment Agency)</td>
</tr>
<tr>
<td></td>
<td><strong>Innovator:</strong> Ivana Cattaneo, Executive Director, Oncology Policy &amp; Healthcare Systems, Novartis Europe</td>
</tr>
<tr>
<td></td>
<td><strong>CRC:</strong> Iva Kirac, Surgical oncologist at University, Hospital for Tumours, UHC Sestre milosrdnice, Croatia</td>
</tr>
<tr>
<td></td>
<td><strong>Patient:</strong> Jana Pelouchová, Co-founder of CML Advocates Network</td>
</tr>
<tr>
<td>10:00-11:00</td>
<td><strong>GROUP 2:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Delia Nicoară MD, PhD</strong>, Public Health Specialist at The Oncology Institute “Prof. Dr. Ion Chiricuţă”, Cluj-Napoca, Romania</td>
</tr>
<tr>
<td></td>
<td><strong>Artificial Intelligence:</strong> Manuel Ottaviano, Assistant Professor Universidad Politécnica de Madrid</td>
</tr>
<tr>
<td></td>
<td><strong>Rare Cancer:</strong> Paolo G. Casali, Director of the Medical Oncology Unit 2 at the Istituto Nazionale Tumori, Milan, Italy</td>
</tr>
<tr>
<td></td>
<td><strong>Lung Cancer:</strong> Amy C. Moore, PhD, VP, Global Engagement and Patient Partnerships · LUNGevity Foundation</td>
</tr>
<tr>
<td></td>
<td><strong>Oncogenomics &amp; Epigenetics:</strong> Patrizio Giacomini, M.D. IRCCS Istituto Nazionale Tumori Regina Elena. Rome, Italy</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Long break and Networking</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 13:30-15:30 | **DEBATE 6: CAN.HEAL - Putting Patients at the Center & EU HEALTH DATA SPACE**<br>Setting the framework: Marc Van den Bulcke, Project Coordinator, CanHeal<br>Nicolás Gonzále
Casares, Group of the Progressive Alliance of Socialists and Democrats in the European Parliament<br>Klaus Pantel, Chairman of the Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf<br>Saila Rinne, Head of Policy Sector, European Commission<br>Suzette DELALOGE, Medical Oncologist, Director, Interception Programme, Department of Cancer Medicine, Institut Gustave Roussy<br>Rosa Giuliani, Medical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust, London, UK<br>Ernesto Samuel Nadal Alforja, Catalan Institute of Oncology, L’Hospitalet, Spain<br>Arnaud Bayle, Medical oncologist, Drug Development Department (DITEP), Gustave Roussy Cancer Center (Villejuif, France) |
| Q&A |                                                                                               |
| 15:30-16:00 | **Closing & Thanks**<br>Núria Malats, head of the Genetic and Molecular Epidemiology Group at the Spanish National Cancer Research Centre (CNIO)** |
Brussels Address: Avenue de l'Armee Legerlaan 10 1040 Brussels, Belgium

Email: denishorgan@euapm.eu